A 40-year-old shared progress pictures showing results after 3.5 months of using dutasteride for hair loss. The conversation likely discusses this specific treatment and its effects on hair regrowth.
The user has been using 1mg finasteride daily, 0.05% tretinoin, and 5% topical minoxidil for hair loss. They've seen hairline recession with minoxidil but also new baby hairs, indicating a positive response.
User experienced slow gains with topical fin+min, switched to topical dut+min, and considered adding Eucapil. Another user suggested DUT may be less effective topically due to high molar mass and mentioned Fluridil as a weak anti-androgen that could help.
Tretinoin alone has led to hair regrowth in the temples and hairline. The user is considering oral minoxidil or dutasteride but prioritizes health first.
The conversation is about a person's nearly 5-month progress using finasteride, minoxidil, some vitamins, and occasional microneedling to treat hair loss, with noticeable improvement in hair growth. They also mention not using creatine or performance-enhancing drugs.
A user had their first dutasteride mesotherapy session in Spain to recover hair on the temple area, with plans for monthly sessions and continued use of topical Minoxidil. If no results are seen in 8 months, they will switch to oral Minoxidil and finasteride.
Kintor Pharma completed enrolling subjects for a Phase III trial of KX-826 for male hair loss treatment. The trial includes a 24-week treatment period and a 4-week safety follow-up, with results expected in about 6-7 months.
The user has been using finasteride and minoxidil for 7 months, seeing thicker hair but no temple regrowth, and is considering switching to dutasteride. Another person suggested trying microneedling on the temples before changing medications.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.
The user is unsatisfied with their hair transplant and is considering another transplant, PRP, exosomes, or stem cells. They currently use topical minoxidil, dutasteride, and tretinoin.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
People are experimenting with high doses of dutasteride, with some reporting halted hair loss and regrowth. Others are combining it with treatments like minoxidil and finasteride, noting varying results and side effects.
The user plans to use a combination of tretinoin, topical minoxidil, and topical finasteride for hair loss treatment. They seek advice on application order, timing, and tretinoin dosage.
Several new hair loss treatments are in development, with Cosmo Breezula and Kintor KX826 being the furthest along, expected to be commercialized by 2027. Veradermics is the only treatment in pill form, while others like KX/GT/Breezula will be topical.
A dutasteride simulator predicts that daily 0.5 mg dosing results in higher DHT suppression compared to less frequent dosing. Twice-weekly dutasteride may be as effective as finasteride 5 mg, providing a balance between efficacy and ease of use.
The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.
The user reported modest hair improvement using 1 mg finasteride daily, topical minoxidil twice daily, and weekly microneedling over seven months. Other users discussed their own experiences and encouraged patience, with some suggesting additional treatments like dutasteride and dermarolling.
A 25-year-old male has been using finasteride since October 2022 to combat diffuse thinning and hairline recession, experiencing initial shedding but later stabilization. He plans to add oral minoxidil to improve hair density and is open to trying dutasteride if necessary, with minimal side effects reported.
A new topical Dutasteride with 20 times better scalp absorption being developed and tested for release in 2023; use of existing drugs, such as Minoxidil and finasteride; and mesotherapy as an alternative hair loss treatment.
The positive effects of one year of treatments with topical minoxidil and oral finasteride for hair loss, with encouraging progress pictures as evidence.
The conversation is about someone using Dutasteride, oral Minoxidil, and Tretinoin for hair loss, and they also stopped antipsychotics and treated an H. pylori infection. They feel there has been progress in their hair growth over two months.
A user is considering mixing Stemoxydine, RU-58841, Alfatradiol, and Tretinoin into a single topical solution for hair loss. They are concerned about potential interactions that could reduce the effectiveness of these ingredients.
The user was diagnosed with DUPA and initially treated with finasteride, then switched to dutasteride which worsened their hair loss. They are now returning to finasteride and adding treatments including oral minoxidil, Proscar, Viviscal, pumpkin seed oil, LLLT, and Nizoral shampoo, hoping for hair regrowth.
A user switched from finasteride to dutasteride, experiencing significant shedding initially but noticing improved hair health and thickness over time. They also use minoxidil, both oral and topical, and report no significant side effects from the treatments.
The user shared their 2-year progress using finasteride and minoxidil, with significant improvement after adding dutasteride in the last year. They advise persistence with the treatment despite initial setbacks.
The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.
The conversation discusses a hair loss treatment regimen including finasteride, dutasteride, minoxidil, tretinoin, microneedling, and red light therapy. The user plans to update on progress after eight months.
User shares one-year hair transplant results with 3633 FUE grafts. Responses discuss improved appearance, hairline looking pluggy, and doctor's location in Ottawa, Canada.
A hair loss regimen that includes oral dutasteride and topical minoxidil, as well as occasional dermapen treatments; the user inquires about when they noticed most regrowth.
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.